Cowen & Co. analyst Chris Shibutani maintained a Buy rating on G1 Therapeutics Inc (GTHX) on March 1. The company’s shares closed yesterday at $20.71, close to its 52-week low of $15.21.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 4.7% and a 47.6% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Five Prime Therapeutics, Nektar Therapeutics, and United Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for G1 Therapeutics Inc with a $58.50 average price target, implying a 182.5% upside from current levels. In a report issued on March 1, H.C. Wainwright also maintained a Buy rating on the stock with a $72 price target.
See today’s analyst top recommended stocks >>
Based on G1 Therapeutics Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $24.09 million. In comparison, last year the company had a GAAP net loss of $16.98 million.
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of GTHX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage pharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
